Wyoming’s Stem Cell Freedom Act, Senate File 48, was passed during the 2026 budget session and signed into law. It creates a new article of the Wyoming statutes, W.S. 35-4-1101 through 35-4-1106, and it takes effect July 1, 2026. The Act authorizes physicians to recommend and perform certain non-FDA-approved stem cell therapies and shields a compliant physician’s license from state disciplinary action. With the effective date close, any Wyoming physician considering this pathway has a narrow window to get the prerequisites in place. This post lays out what the Act actually says.
TLDR: Wyoming SF 48, codified at W.S. 35-4-1101 through 35-4-1106 and effective July 1, 2026, lets a physician perform non-FDA-approved stem cell therapy using autologous mesenchymal stem cells if five conditions are met: the therapy is under a current IRB approval or qualifies as an investigational drug, biological product, or device; the cells are manufactured under cGMP standards; a physician-patient relationship exists; the physician is registered with the Wyoming State Board of Medicine; and written informed consent is obtained. The Board cannot discipline a physician’s license solely for compliant practice. The IRB step is the tightest timeline item. Banking adipose tissue does not enroll a patient in therapy and does not guarantee any future eligibility, access, or benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently holds FDA approval for the conditions discussed in this article. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
There are 27 days between this post’s publication and the Act’s effective date. That matters because one of the Act’s conditions, IRB approval, cannot be obtained overnight. A physician who wants to be operating lawfully under SF 48 on July 1 has to have started the slower prerequisites already. The sections below separate what the Act grants from what it still requires.
What the Act Does
SF 48 authorizes a patient to receive, and a physician to perform, stem cell therapy that has not been approved by the FDA, provided the Act’s conditions are met. The Act defines “stem cell therapy” narrowly: it means treatment involving the use of autologous mesenchymal stem cells, including their collection, processing, cultural expansion, manufacturing, storage, and therapeutic use. “Autologous” means the patient’s own cells. The Act expressly excludes any biological material derived from an abortion. This is a meaningfully different scope from a general stem cell authorization; the Act is about a patient’s own mesenchymal cells, not donor or perinatal products.
The Act also shields the practicing physician. The Wyoming State Board of Medicine may not revoke, decline to renew, suspend, or otherwise act against a physician’s license based solely on the physician’s recommendation of, or performance of, stem cell therapy, so long as the recommendation or procedure is consistent with medical standards of care and the physician is registered under the Act. Separately, no state official may prohibit a patient’s access to stem cell therapy, and the Act creates no private cause of action against a person who is properly complying with the Act and the standard of care.
The Five Conditions a Physician Must Meet
To operate within the Act’s protections, all of the following must be true.
- IRB approval or investigational status. The therapy must be conducted in accordance with a current Institutional Review Board approval, or the stem cells must qualify as an investigational drug, biological product, or device. The Act defines the latter precisely: a product that has successfully completed phase one of a clinical trial but is not yet approved for general use by the FDA and remains under investigation. This is the most operationally significant condition for a solo or small-group practice, and it is the one with the longest lead time.
- cGMP manufacturing. The stem cells must be manufactured and handled in accordance with current good manufacturing practice standards. The Act ties cGMP to applicable federal law, so the practical requirement is documentation from the manufacturing source establishing cGMP compliance.
- Physician-patient relationship. A documented physician-patient relationship must exist between the administering physician and the person receiving therapy.
- Physician registration. The physician must be registered with the Wyoming State Board of Medicine to provide stem cell therapy under the Act. The Act separately directs the Board to operate and publish a public registry of qualified physicians, so registration is both a precondition and a matter of public record.
- Written informed consent. The patient or the patient’s legal representative must provide written informed consent acknowledging the nature and character of the proposed therapy, that the therapy is not FDA-approved, the potential benefits, risks, and complications, and the patient’s financial responsibility for paying for the therapy.
The Act also requires that the therapy be administered by a physician or under a physician’s direct supervision, with non-administration activities supervised by a physician.
The License Protection Provision, Read Carefully
The protection in W.S. 35-4-1104 is built around the word “solely.” The Board cannot act against a license based solely on compliant recommendation or performance of stem cell therapy. It does not immunize a physician for other conduct. Negligent care, failure to meet the standard of care, or failure to satisfy the Act’s own conditions are not protected. The Act is explicit that it does not create a private liability shield: it bars a private cause of action only against a person who is properly performing under the Act and the standard of care. A physician who treats the Act as blanket immunity has misread it.
What the Act Does NOT Do
| What SF 48 Does | What SF 48 Does NOT Do |
|---|---|
| Authorizes physician-performed non-FDA-approved therapy using autologous mesenchymal stem cells | Remove the IRB-approval-or-investigational-status condition |
| Protects a license from action based solely on compliant recommendation or performance | Protect against action for failing the Act’s own conditions or the standard of care |
| Applies across therapeutic uses without Florida-style condition limits | Remove the cGMP manufacturing requirement |
| Bars state officials from blocking patient access | Create a private liability shield for negligent care |
| Directs a public registry of qualified physicians | Override federal FDA authority to enforce federal law |
How This Compares to Florida SB 1768
Florida and Wyoming reached similar destinations by different routes. Florida’s SB 1768 limits authorized therapy to orthopedics, wound care, and pain management; Wyoming imposes no comparable condition list but instead narrows scope by cell type, autologous mesenchymal stem cells only. The Florida regulatory picture and the broader physician case for banking are laid out in the overview of why physicians add adipose banking.
Florida requires the sourcing facility to be FDA-registered and accredited by one of four named bodies and requires a post-thaw viability report before each use. Wyoming does not specify that accreditation list or a viability report; it requires cGMP manufacturing and the IRB-or-investigational condition instead. Both require a physician-patient relationship and written informed consent, and both provide license protections for compliant practice. The Wyoming registration-and-registry requirement has no direct Florida analogue. The market backdrop driving physician interest in both states is covered in the regenerative medicine market for physicians.
The IRB Pathway for Small Practices
A community physician without a hospital or academic IRB affiliation will generally need an independent IRB. Independent boards that review this kind of protocol include Advarra, WCG, Solutions IRB, and Salus IRB. The basic sequence is: develop a written research protocol, apply to the independent IRB, complete review (expedited review often runs a few weeks; full-board review longer), implement the protocol exactly as approved, and submit continuing review reports on the board’s schedule. Given the July 1, 2026 effective date, a physician who has not yet started this process is already behind, and the realistic posture is to begin immediately or to plan for a later start date.
For the alternative investigational route, identifying products with active investigational status and expanded-access policies is aided by the Reagan-Udall Expanded Access Navigator. How the access pathways for investigational products work is covered in the discussion of expanded access programs.
Pre-July 1 Action Checklist
- Confirm current IRB status, or initiate an independent IRB application immediately.
- Verify that any stem cell product source uses cGMP-compliant manufacturing, and obtain documentation.
- Register with the Wyoming State Board of Medicine to provide stem cell therapy under the Act.
- Establish a physician-patient relationship documentation standard.
- Draft a Wyoming-specific written informed consent form covering all four statutory acknowledgments, including financial responsibility.
- Consult Wyoming healthcare counsel on the Act’s requirements and the registration process.
- Train staff on the consent, documentation, and supervision workflow.
- Review any advertising for compliance with the Act and applicable federal and platform rules.
Frequently Asked Questions
Does SF 48 cover all stem cell therapies?
No. The Act defines stem cell therapy as treatment using autologous mesenchymal stem cells, the patient’s own cells. Donor, perinatal, and abortion-derived materials are outside its scope, and abortion-derived material is expressly excluded.
Is the Act in effect now?
The Act was passed and signed during the 2026 session and takes effect July 1, 2026. Before that date, the authorization and protections it creates are not yet operative.
Does the license protection mean a physician cannot be disciplined?
No. The Board cannot act based solely on compliant recommendation or performance of stem cell therapy. A physician remains accountable for the standard of care and for meeting the Act’s own conditions, including registration.
Does banking adipose tissue satisfy the Act?
No. Banking is the preservation of a patient’s own tissue and is separate from therapeutic use. The Act’s conditions apply at the point of therapeutic administration, not at the point of banking, and banking guarantees no future eligibility, access, or benefit.
Key Takeaways
The Wyoming Stem Cell Freedom Act opens a real but conditioned pathway, effective July 1, 2026, for physician-performed therapy using a patient’s own mesenchymal stem cells. The five conditions, IRB approval or investigational status, cGMP manufacturing, a physician-patient relationship, registration with the State Board of Medicine, and written informed consent, are cumulative, and the license protection applies only to physicians who meet them and practice within the standard of care. The word “solely” in the protection clause is doing heavy lifting: this is not immunity. For a physician planning to operate on the effective date, the IRB condition is the binding constraint on the calendar, and registration with the Board is a hard prerequisite that also becomes public record. The Act does not touch the federal layer; the FDA’s authority is unchanged. And none of it alters the basic fact that banking adipose tissue is a preservation decision separate from any treatment, with no guarantee of future use.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Wyoming physicians weighing how tissue preservation fits a compliant model can contact Save My Fat to discuss the operational side. Service and processing details are available at https://savemyfat.com/pricing/.
Save My Fat partners with L2 Bio for laboratory processing and storage. Requirements under Wyoming SF 48 should be reviewed alongside federal FDA regulations; the Act does not limit the FDA’s authority to enforce federal law.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
